*Please scroll down to the bottom of the page for the final deliverable.
Storyboard
If your scientific research involves the use of antibodies
Or if you are a company involved with the antibody reagents market
You're probably aware that the field of recombinant antibody technology is rapidly progressing
Because of increasing interest in human therapeutic use.
Furthermore, an advancing ability to select specific human antibodies
And to improve their affinity, stability, and expression level is futher boosting the popularity of this field.
But here's the problem with traditional antibodies.
They are only stable over a narrow pH and temperature range.
And their large size means they are excluded from binding to many active sites on proteins.
With this in mind, we at Abcore proudly present to you our flagship product.
Single-domain antibodies.
Single-domain antibodies are heat stable up to 70 °C.
They are stable over a wide pH range.
Compared to traditional antibodies which are approximately 150 kDa in size, they are only 15 kDa.
Which means they can recognize targets in active sites that are not accessible to traditional antibodies.
Here, you can see the structure of a single-domain antibody compared to a traditional antibody.
Notice how the single-domain antibody contains only the antigen-binding variable domain,
also called the VHH domain.
Single-domain antibodies also have the following advantages over regular antibodies.
They can penetrate into tissue much more rapidly.
They are less likely to be immunotoxic.
They can easily be converted into different formats
Such as Fc fusion proteins
And heterodimers.
They are more suitable for oral delivery
And use in diagnostic devices.
They are able to pass the renal filter, resulting in their rapid blood clearance.
Which is advantageous when using the single-domain antibody coupled to a toxic substance.
They can be used as crystallization chaperones in the structure determination of challenging target proteins that would prove unsolvable using conventional strategies.
They can be used as introbodies to target intracellular proteins.
The way in which we produce single-domain antibodies for you at Abcore is as follows.
We start by immunizing llamas with the immunogen.
We use llamas because they naturally produce heavy chain-only antibodies,
which are functional antibodies devoid of light chains.
The llamas then go through a 90-day schedule, during which they are boosted
And bled to determine their specific antisera titre.
Once the antisera titre up
The peripheral blood mononuclear cells, also called PBMCs, are isolated
Total RNA is isolated from that
And cDNA is prepared.
The VHH genes are amplified from cDNA using proprietary PCR primers that cover the genetic diversity in this complex region.
The PCR product is then cloned into a phagemid vector
Creating the VHH Antibody Library.
The library is scanned through multiple rounds of affinity panning
Positive clones are identified via ELISA and then sequenced.
These clones are used to produce expressed, purified, llama monoclonal single-domain antibodies.
At Abcore, we give you the unique choice of selecting one of six single-domain antibody production options.
1: Fresh llama blood.
2: PBMCs
3: RNA and cDNA
4: SDA Antibody Library
5: Positive Clones
6: Large-Scale Production
For information about our pricing tiers, please enter your name, email, phone number, and select the production option you are interested in and click Submit.
Thank you for watching.
Thank you for choosing Abcore.
Video Final Deliverable:
Suggested Landing Page Design:
